Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

580
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
580
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

610
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
610
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

828
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
828
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

1.2K
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

546
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
546
Teratogenicity01:07

Teratogenicity

4.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Renal Replacement Therapy in Lupus Nephritis-Related End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.

ACR open rheumatology·2025
Same author

2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.

Arthritis care & research·2025
Same author

A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development.

Arthritis care & research·2025
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Related Experiment Video

Updated: Feb 21, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.2K

Biologic Disease-Modifying Antirheumatic Drug Use During Pregnancy and Lactation.

Caroline H Siegel1, Lisa R Sammaritano

  • 1Division of Rheumatology, Hospital for Special Surgery, and the Department of Medicine, Weill Cornell Medicine, New York, New York.

Obstetrics and Gynecology
|February 19, 2026
PubMed
Summary
This summary is machine-generated.

Biologic disease-modifying antirheumatic drugs (bDMARDs) are increasingly used for autoimmune rheumatic diseases in women of childbearing age. Guidelines support bDMARD use during pregnancy to control maternal disease, with TNF inhibitors showing the most safety data.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K
Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring
09:09

Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring

Published on: August 17, 2022

2.4K

Related Experiment Videos

Last Updated: Feb 21, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.2K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K
Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring
09:09

Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring

Published on: August 17, 2022

2.4K

Area of Science:

  • Rheumatology
  • Immunology
  • Maternal-Fetal Medicine

Background:

  • Autoimmune rheumatic diseases (ARDs) predominantly affect women of reproductive age.
  • Managing ARDs during pregnancy requires balancing maternal disease control with fetal safety.
  • Biologic disease-modifying antirheumatic drugs (bDMARDs) are increasingly utilized alongside conventional therapies.

Purpose of the Study:

  • To review the use of bDMARDs in pregnant and lactating women with ARDs.
  • To assess the safety of bDMARDs during pregnancy and their impact on infant vaccination post-exposure.
  • To synthesize current evidence and guideline recommendations for managing ARDs with bDMARDs during pregnancy.

Main Methods:

  • Literature synthesis of current evidence on bDMARD use in pregnancy and lactation.
  • Review of professional society guidelines for ARD treatment during pregnancy.
  • Analysis of safety data for bDMARDs, particularly TNF inhibitors, during gestation and postpartum.

Main Results:

  • Current guidelines generally support the use of bDMARDs during pregnancy and lactation to maintain maternal disease control.
  • Tumor necrosis factor inhibitors (bDMARDs) possess the most extensive safety evidence for use during pregnancy and lactation.
  • While teratogenicity is unlikely, potential neonatal immune effects and unknown in utero exposure consequences warrant consideration.

Conclusions:

  • The benefits of using bDMARDs often outweigh the risks, especially for refractory maternal disease.
  • Evidence for newer bDMARDs with novel mechanisms of action is limited.
  • Further research is essential for personalized counseling and shared decision-making in ARD management during pregnancy.